Tenaya reports first revenue, stronger gene therapy trial data, but cash drops to $81M

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

Key Changes

• high

  Cash declined to $80.9M (from $88.2M a year ago) and committed SVB loan access expired; only $20M discretionary tranche remains, subject to lender approval. Company maintains 12-month runway guidance despite reduced liquidity sources.

  MD&A: Liquidity; Risk Factors: Loan Agreement verify on EDGAR →
• high

  MyPEAK-1 trial shows all three Cohort 1 patients achieved 21-39% reductions in heart wall thickness and up to 74% decline in cardiac troponin (vs. prior >60% in two patients). Higher-dose Cohort 2 shows 2x greater gene delivery and 14% protein increase at Week 12.

  MD&A: TN-201 Clinical Updates verify on EDGAR →
• high

  RIDGE-1 trial data shows two of three patients experienced 46-89% reductions in premature ventricular contractions, a key arrhythmia measure in ARVC. Independent safety board endorsed expansion at either dose level.

  MD&A: TN-401 Clinical Updates verify on EDGAR →